Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ezabenlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ezabenlimab overview
Ezabenlimab (BI-754091) is under development for the treatment of solid tumors including gastroesophageal (GE) junction cancer, gastric cancer, metastatic colorectal cancer, esophageal cancer, non squamous non-small cell lung cancer, melanoma, liposarcoma, bladder cancer, colon cancer, breast cancer, triple negative breast cancer, cholangiocarcinoma, pancreatic cancer, ovarian cancer, renal cell cancer, sarcoma, prostate cancer, melanoma, undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer and endometrial cancer. It is administered intravenously. The therapeutic candidate is a monoclonal antibody and targets programmed cell death protein 1 (PD-1). The drug candidate was also under development for metastatic squamous cell carcinoma of the anal canal and head and neck squamous cell carcinoma.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. Boehringer is headquartered in Ingelheim am Rhein,Rhineland-Palatinate, Germany.
For a complete picture of Ezabenlimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
